27 February 2023 – Neil Clark speaks to Endpoint – ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’

Posted on by Kirsty Richardson

Destiny Pharma’s CEO, Neil Clark, speaks to Endpoint.  For the full article ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’, please click here